Atossa Therapeutics Reports Substantial 2025 Loss and Cash Burn Amidst Clinical Progress
ATOS sits 39% above its 52-week low of $3.76.
Summary
Atossa Therapeutics reported a substantial increase in net loss and significant cash burn for 2025, underscoring financial pressures despite achieving key regulatory designations for its (Z)-endoxifen program.
Key Events · Earnings and Guidance · ATOS
-
Increased Net Loss for 2025
The company reported a net loss of $34.77 million for the year ended December 31, 2025, a significant increase from $25.50 million in 2024.
-
Substantial Cash Burn
Cash and cash equivalents decreased by nearly $30 million, from $71.08 million at year-end 2024 to $41.29 million at year-end 2025.
-
Operational Expenses Rise
Total operating expenses increased by 34% to $37.1 million, driven by a 50% rise in R&D and an 18% increase in G&A expenses.
-
Key Regulatory Designations Achieved
Received FDA Rare Pediatric Disease and Orphan Drug designations for (Z)-endoxifen for Duchenne Muscular Dystrophy, offering potential future value and regulatory support.
Analysis · ATOS · Life Sciences
Atossa Therapeutics reported a significant increase in its net loss for the year ended December 31, 2025, reaching $34.77 million, up from $25.50 million in the prior year. This was driven by a 34% increase in total operating expenses, with R&D expenses rising 50% and G&A expenses up 18%. Critically, the company's cash and cash equivalents decreased by nearly $30 million, from $71.08 million to $41.29 million, indicating a substantial cash burn. These financial results provide crucial context for the company's recent proposal for a reverse stock split, as disclosed in a PRE 14A filing on March 20, 2026, suggesting a need to address its stock price and maintain Nasdaq listing requirements. While the company announced positive clinical milestones, including FDA Rare Pediatric Disease and Orphan Drug designations for (Z)-endoxifen in Duchenne Muscular Dystrophy, which offer potential future value like a Priority Review Voucher, the immediate financial deterioration and cash runway concerns are paramount for investors.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 36.1% of the 1051 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.56%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ATOS was trading at $5.21 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $46.7M. The 52-week trading range was $3.76 to $19.35. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.